- Home
- AVTX
as 03-25-2025 12:30pm EST
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | ROCKVILLE |
| Market Cap: | 88.4M | IPO Year: | 2015 |
| Target Price: | $34.33 | AVG Volume (30 days): | 106.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -20.91 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.60 - $34.46 | Next Earning Date: | 05-12-2025 |
| Revenue: | $441,000 | Revenue Growth: | -77.08% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Avalo Therapeutics Inc. News
AVTX Breaking Stock News: Dive into AVTX Ticker-Specific Updates for Smart Investing
GlobeNewswire
6 days ago
Avalo Reports 2024 Financial Results and Recent Business Updates
GlobeNewswire
a month ago
Avalo Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire
2 months ago
Avalo Therapeutics to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference
GlobeNewswire
3 months ago
Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer
TipRanks
3 months ago
Avalo Therapeutics initiated with a Buy at BTIG
GlobeNewswire
4 months ago
Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants
GlobeNewswire
4 months ago
Avalo Therapeutics to Present at Upcoming Investor Conferences
GlobeNewswire
5 months ago
Avalo Reports Third Quarter 2024 Financial Results and Recent Business Updates
Compare AVTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AVTX Avalo Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.